AnGes, Inc. (4563.T)
JPY 78.0
(5.41%)
JPY 78.0
(5.41%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.9 Billion JPY | -33.55% |
| 2022 | 13.39 Billion JPY | -14.34% |
| 2021 | 15.63 Billion JPY | 178.46% |
| 2020 | 5.61 Billion JPY | 60.03% |
| 2019 | 3.5 Billion JPY | 0.64% |
| 2018 | 3.48 Billion JPY | 0.33% |
| 2017 | 3.47 Billion JPY | -31.89% |
| 2016 | 5.1 Billion JPY | 15.39% |
| 2015 | 4.42 Billion JPY | 45.82% |
| 2014 | 3.03 Billion JPY | 76.0% |
| 2013 | 1.72 Billion JPY | -17.97% |
| 2012 | 2.1 Billion JPY | 156.39% |
| 2011 | 819.31 Million JPY | 5.77% |
| 2010 | 774.59 Million JPY | -0.52% |
| 2009 | 778.65 Million JPY | 15.4% |
| 2008 | 674.74 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.73 Billion JPY | -11.36% |
| 2024 Q2 | 1.85 Billion JPY | 56.1% |
| 2023 Q1 | 3.02 Billion JPY | -1.88% |
| 2023 Q4 | 1.95 Billion JPY | -40.27% |
| 2023 Q2 | 2.91 Billion JPY | -3.67% |
| 2023 FY | 8.9 Billion JPY | -33.55% |
| 2023 Q3 | 3.27 Billion JPY | 12.33% |
| 2022 Q2 | 5.57 Billion JPY | 57.44% |
| 2022 Q4 | 3.08 Billion JPY | -6.72% |
| 2022 Q1 | 3.54 Billion JPY | 2.06% |
| 2022 FY | 13.39 Billion JPY | -14.34% |
| 2022 Q3 | 3.3 Billion JPY | -40.69% |
| 2021 Q2 | 3.91 Billion JPY | 7.82% |
| 2021 Q4 | 3.47 Billion JPY | -24.84% |
| 2021 FY | 15.63 Billion JPY | 178.46% |
| 2021 Q3 | 4.61 Billion JPY | 17.9% |
| 2021 Q1 | 3.63 Billion JPY | 32.29% |
| 2020 Q4 | 2.74 Billion JPY | 150.49% |
| 2020 Q2 | 797.37 Million JPY | -18.34% |
| 2020 Q1 | 976.42 Million JPY | 7.07% |
| 2020 Q3 | 1.09 Billion JPY | 37.49% |
| 2020 FY | 5.61 Billion JPY | 60.03% |
| 2019 Q1 | 957.96 Million JPY | -13.25% |
| 2019 FY | 3.5 Billion JPY | 0.64% |
| 2019 Q3 | 799.22 Million JPY | -4.91% |
| 2019 Q2 | 840.45 Million JPY | -12.27% |
| 2019 Q4 | 911.92 Million JPY | 14.1% |
| 2018 Q2 | 667.25 Million JPY | 6.27% |
| 2018 Q1 | 627.87 Million JPY | 4.4% |
| 2018 Q3 | 1.08 Billion JPY | 63.01% |
| 2018 FY | 3.48 Billion JPY | 0.33% |
| 2018 Q4 | 1.1 Billion JPY | 1.53% |
| 2017 Q2 | 711.13 Million JPY | -34.06% |
| 2017 FY | 3.47 Billion JPY | -31.89% |
| 2017 Q4 | 601.4 Million JPY | -44.56% |
| 2017 Q3 | 1.08 Billion JPY | 52.54% |
| 2017 Q1 | 1.07 Billion JPY | -11.26% |
| 2016 Q4 | 1.21 Billion JPY | 20.68% |
| 2016 Q3 | 1 Billion JPY | -39.18% |
| 2016 Q2 | 1.65 Billion JPY | 35.18% |
| 2016 Q1 | 1.22 Billion JPY | 1.68% |
| 2016 FY | 5.1 Billion JPY | 15.39% |
| 2015 Q2 | 1.15 Billion JPY | 14.51% |
| 2015 FY | 4.42 Billion JPY | 45.82% |
| 2015 Q1 | 1 Billion JPY | 24.1% |
| 2015 Q3 | 1.05 Billion JPY | -8.09% |
| 2015 Q4 | 1.2 Billion JPY | 13.73% |
| 2014 Q1 | 531.75 Million JPY | 11.89% |
| 2014 FY | 3.03 Billion JPY | 76.0% |
| 2014 Q2 | 611 Million JPY | 14.91% |
| 2014 Q4 | 810.91 Million JPY | -24.85% |
| 2014 Q3 | 1.07 Billion JPY | 76.62% |
| 2013 Q4 | 475.24 Million JPY | 34.31% |
| 2013 FY | 1.72 Billion JPY | -17.97% |
| 2013 Q3 | 353.83 Million JPY | -23.67% |
| 2013 Q2 | 463.53 Million JPY | 7.64% |
| 2013 Q1 | 430.62 Million JPY | -69.59% |
| 2012 Q2 | 220.47 Million JPY | -7.35% |
| 2012 Q4 | 1.41 Billion JPY | 525.93% |
| 2012 Q3 | 226.22 Million JPY | 2.61% |
| 2012 FY | 2.1 Billion JPY | 156.39% |
| 2012 Q1 | 237.96 Million JPY | -5.79% |
| 2011 Q4 | 252.59 Million JPY | 30.56% |
| 2011 Q1 | 190.07 Million JPY | 0.8% |
| 2011 Q2 | 183.16 Million JPY | -3.64% |
| 2011 Q3 | 193.47 Million JPY | 5.63% |
| 2011 FY | 819.31 Million JPY | 5.77% |
| 2010 Q1 | 188.91 Million JPY | -25.03% |
| 2010 Q2 | 208.68 Million JPY | 10.46% |
| 2010 Q4 | 188.56 Million JPY | 0.07% |
| 2010 Q3 | 188.43 Million JPY | -9.71% |
| 2010 FY | 774.59 Million JPY | -0.52% |
| 2009 Q3 | 173.32 Million JPY | -0.82% |
| 2009 FY | 778.65 Million JPY | 15.4% |
| 2009 Q2 | 174.75 Million JPY | -2.14% |
| 2009 Q4 | 251.99 Million JPY | 45.39% |
| 2009 Q1 | 178.57 Million JPY | 0.0% |
| 2008 FY | 674.74 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -593.064% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -1443.34% |
| GNI Group Ltd. | 9.32 Billion JPY | 4.507% |
| Linical Co., Ltd. | 2.7 Billion JPY | -229.079% |
| Trans Genic Inc. | 2.15 Billion JPY | -312.173% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -497.0% |
| Soiken Holdings Inc. | 3.07 Billion JPY | -189.873% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -379.393% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -843.95% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 53.61% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -2055.553% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -812.701% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | -246.717% |
| CanBas Co., Ltd. | 278 Million JPY | -3102.236% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -679.846% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -389.684% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -455.083% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -274.978% |
| PeptiDream Inc. | 9.68 Billion JPY | 8.104% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -354.058% |
| Ribomic Inc. | 1.1 Billion JPY | -705.127% |
| SanBio Company Limited | 4.53 Billion JPY | -96.127% |
| Healios K.K. | 3.48 Billion JPY | -155.297% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -670.93% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -567.1% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -534.304% |
| StemRIM | 2.07 Billion JPY | -328.816% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -353.386% |
| FunPep Company Limited | 313.82 Million JPY | -2736.718% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -829.239% |
| Stella Pharma Corporation | 963.98 Million JPY | -823.481% |
| TMS Co., Ltd. | 943.25 Million JPY | -843.778% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -716.753% |
| Cuorips Inc. | 598.11 Million JPY | -1388.371% |
| K Pharma,Inc. | 543.94 Million JPY | -1536.611% |
| Takara Bio Inc. | 23.9 Billion JPY | 62.76% |
| ReproCELL Incorporated | 1.51 Billion JPY | -487.987% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -651.883% |
| StemCell Institute Inc. | 1.16 Billion JPY | -666.031% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -484.796% |
| CellSeed Inc. | 804.93 Million JPY | -1005.96% |